African Americans Fighting Alzheimer’s in Midlife (AA-FAIM)

1项目概要 2非裔美国人在中年与阿尔茨海默氏症作斗争（AA-FAIM）的首要目标是 3促进及时有效地检测阿尔茨海默病（AD）和相关痴呆症（ADRD）， 4人口，并增加纳入ADRD研究的黑人成年人。在美国被种族化为黑人， 5与认知能力下降和ADRD的风险是非西班牙裔白人的两倍相关。然而，由于黑 6美国人在ADRD研究中的招募和代表性严重不足，我们的研究仍然存在差距。 7了解临床前AD病理生理学的流行理论的普遍性（例如，淀粉样蛋白 （8）对黑人患者。为了解决这些差距，我们必须从布莱克那里获得必要的生物标志物数据。 9名参与者，并提高黑人参与者的包容性，以科学的严谨性审查招聘/保留。在 目的1，我们将探索临床前淀粉样变性在预测黑人队列中认知能力下降方面的相关性， 11个比较模型，考虑了（a）临床前AD病理学，（B）血管风险因素，（c）心理社会因素 12个因素，和（d）认知标志物在预测认知能力下降的400名黑人成年人的队列。目标2将 13检查血浆A β 42/40和淀粉样蛋白PET阳性（PET A+）之间的关联， 14黑人参与者中临床前AD的慢性/EAOA（淀粉样蛋白发作的估计年龄）模型。我们将 15研究血浆A β 42/40和并发PET A+之间的相关性，并评估较长的淀粉样蛋白是否 16慢性和/或早期EAOA与加速认知衰退有关。目标3审查各项因素 17与成功入组和保留相关。我们将评估认知和信念的模式相对 18到一个新兴的参与者参与模型，并探讨模型结构在预测 19个预期参与决策。随着对AA-FAIM队列的重新投资，我们将继续 20有助于对少数人群中临床前ADRD的新认识。另外可以 21通过与寻求访问这些独特数据的团队合作，进一步利用参与者的贡献。

1 PROJECT SUMMARY 2 The overarching goals of the African Americans Fighting Alzheimer’s in Midlife (AA-FAIM) renewal are to 3 promote timely and valid detection of Alzheimer’s disease (AD) and related dementias (ADRD) in Black 4 populations and to increase inclusion of Black adults in ADRD research. Being racialized as Black in the US is 5 associated with twice the risk of cognitive decline and ADRD relative to non-Hispanic whites. Yet, because Black 6 Americans are substantially under-recruited and under-represented in ADRD research, gaps remain in our 7 understanding of the generalizability of prevailing theories of preclinical AD pathophysiology (e.g. the amyloid 8 hypothesis) to Black patients. To address these gaps, we must obtain essential biomarker data from Black 9 participants and improve inclusion of Black participants, examining recruitment/retention with scientific rigor. In 10 Aim 1, we will explore the relevance of preclinical amyloidosis in predicting cognitive decline in a Black cohort, 11 comparing models considering roles of (a) preclinical AD pathology, (b) vascular risk factors, (c) psychosocial 12 factors, and (d) cognitive markers in predicting cognitive decline in a cohort of 400 Black adults. Aim 2 will 13 examine the association between plasma Aß42/40 and Amyloid PET positivity (PET A+) and test the 14 chronicity/EAOA (estimated age of amyloid onset) model of preclinical AD in Black participants. We will 15 investigate associations between plasma Aß42/40 and concurrent PET A+, and assess whether longer amyloid 16 chronicity and/or earlier EAOA are associated with accelerated cognitive decline. Aim 3 examines factors 17 associated with successful enrollment and retention. We will assess patterns of perceptions and beliefs relative 18 to an emerging model of participant engagement, and explore model constructs’ efficacy in predicting 19 prospective participation decisions. With renewed investment in the AA-FAIM cohort, we will continue 20 contributing to an emerging understanding of preclinical ADRD in a minoritized population. Moreover, we can 21 further leverage our participants’ contributions by partnering with teams seeking access to these unique data.